Literature DB >> 15129986

Evaluation of xanthan and highly substituted galactomannan from M. scabrella as a sustained release matrix.

F Ughini1, I F Andreazza, J L M S Ganter, T M B Bresolin.   

Abstract

A highly substituted galactomannan (G) from Mimosa scabrella Bentham (Man:Gal 1.1:1), isolated from the seeds of a Brazilian leguminous tree and xanthan (X), an exopolysaccharide secreted by Xanthomonas campestris (Keltrol), were evaluated as a hydrophilic matrix system (XG) for controlled release (CR) of diclofenac sodium (DS) in tablets and capsules. The performance of XG (2:1) matrices containing 50 mg (A) or 100 mg (B) of DS was compared with a commercial CR product of DS. The drug release studies were carried out using a dissolution apparatus (paddle method) with gradual increase of pH values, from pH 1.4, to pH 4.0 (after 1 h) and to pH 6.8 (after 2 h). The results suggested the potential of XG systems as release retarding materials, which released 78.6 and 35.1% of drug after 24 h for capsules (A) and tablets (A), respectively. Drug release decreased with the increase of amount of drug and it is dependent of dosage form. Analysis of release data indicate a rather zero-order drug release with the erosion mechanism playing a dominant role.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15129986     DOI: 10.1016/j.ijpharm.2003.11.011

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Release behaviour of propranolol HCl from hydrophilic matrix tablets containing psyllium powder in combination with hydrophilic polymers.

Authors:  Mohammad R Siahi-Shadbad; Kofi Asare-Addo; Kakali Azizian; Davoud Hassanzadeh; Ali Nokhodchi
Journal:  AAPS PharmSciTech       Date:  2011-09-15       Impact factor: 3.246

2.  Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride.

Authors:  Jaleh Varshosaz; Naser Tavakoli; Fatemeh Kheirolahi
Journal:  AAPS PharmSciTech       Date:  2017-03-08       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.